Delivery Order SPE2DB20D7059-SPE2DB25FGRP4
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,347.84 to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Ondansetron ODT 4 mg tablets in quantities of 30. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of September 4, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count) with a contract ceiling value of $4,122.98. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for completion by September 12, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,683.30 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units) on August 12, 2025, with completion scheduled for August 13, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a pharmaceutical supply requirement within...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 4 mg tablets (30-count supply) with a ceiling value of $1,077.90. This is a firm fixed price delivery order with an ultimate completion date of September 2, 2025, and was awarded on August 29, 2025. The contract carries no set-aside designation and was competitively awarded. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count) with a ceiling value of $9,217.95. This firm fixed-price delivery order represents a non-competitive set-aside and is scheduled for completion by August 14, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order valued at $8,939.49 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packages) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of the company's role as a...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $6,307.77. This firm fixed-price delivery order, which is expected to be completed by September 9, 2025, carries no set-aside designation and represents a competitively awarded contract. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains...
- The Defense Logistics Agency awarded a delivery order valued at $18,470.50 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count packaging). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,614.04 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count packages). This is a firm fixed-price delivery order with an ultimate completion date of September 11, 2025, awarded on September 10, 2025, without set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,174.82 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 8 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order was issued on September 4, 2025, with an ultimate completion date of September 5, 2025. The contract carries no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- SPE2DB20D7059Indefinite Delivery Contract
- SPE2DB20D7059-SPE2DB25FGRP4Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 MG tablets (30-count packaging) under a firm fixed-price contract valued at $3,103.77. The order was competitively awarded without set-aside provisions and carries an ultimate completion date of September 12, 2025, just one day after the award date of September 11, 2025. Performance will be executed from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued against AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive portfolio of medications and medical supplies to support military and veteran healthcare systems. The company's extensive federal contract history demonstrates its established capability to fulfill diverse pharmaceutical procurement requirements through competitive processes, positioning it as a key supplier within the Defense Health Agency's medical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 9/11/25 |